2-amino-5-phosphonovalerate has been researched along with Atherosclerotic Parkinsonism in 2 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calabresi, P | 1 |
| Saiardi, A | 1 |
| Pisani, A | 1 |
| Baik, JH | 1 |
| Centonze, D | 1 |
| Mercuri, NB | 1 |
| Bernardi, G | 1 |
| Borrelli, E | 1 |
| Svensson, A | 1 |
| Carlsson, ML | 1 |
2 other studies available for 2-amino-5-phosphonovalerate and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cerebral Cortex; Corpus | 1997 |
Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation.
Topics: 2-Amino-5-phosphonovalerate; Animals; Biogenic Monoamines; Clonidine; Disease Models, Animal; Drug S | 1992 |